Skip to content
Unjha Formulations logo

Unjha Formulations

531762 BSE
Price unavailable

Unjha Formulations (UNJHAFOR) share price was ₹26.99 at the 28 Oct 2026 close; market capitalisation ₹12.12 Cr; P/E (TTM) 24.99; sector Healthcare. The share price rose 11.2% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 8.8% year on year to ₹3.31 Cr and net profit was ₹0.16 Cr, against ₹0.39 Cr a year earlier (compared with Jun 2025). Promoters held 36.92% of Unjha Formulations in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 62/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹26.99 +2.99 +12.46% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹12.12 Cr
P/E (TTM)
24.99
EBITDA
₹1.10 Cr
Return on Equity
18.34%
Debt to Equity
0
Book Value
₹8.58
EPS (TTM)
₹1.08
52W High
₹36.38
52W Low
₹17.52

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,607.8072.341,75,266 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.30108.071,18,182 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,339.3034.691,11,789 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Unjha Formulations (this company)
—24.9912 Cr3.150.00%18.34%25.02%15 Cr0 Cr
Median 8 companies₹1,767.5034.881,18,034 Cr4.710.47%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

62 Good
Overall score

Data confidence 98/100

Category scores

Quality Strong 76
Returns, margins, earnings quality 22% weight
Valuation Average 50
Cheap vs sector & own history 24% weight
Growth Good 56
Sales & profit trajectory 9% weight
Financial Health Strong 75
Solvency, leverage, coverage 9% weight
Momentum Strong 83
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

2
  • The company has delivered a poor sales growth of 9.37% over past five years.
  • Promoter holding is low: 36.9%

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
4
Bullish
3

Overall

Bearish

Bearish
9
Neutral
4
Bullish
6

Moving Averages

Bearish

Bearish
7
Neutral
0
Bullish
3

Growth Rate

Revenue Growth
12.14% higher than 3Y

change over 1 year

Net Income Growth
75% higher than 3Y

change over 1 year

Cash Flow Change
—

EBITDA Margin Change
55.43%

change over 1 year Operating margin 5.74% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
3.76
4.76
5.55
4.43
3.95
3.78
3.76
2.44
3.63
4.29
4.44
3.33
3.31
Expenses
3.54
4.87
5.14
4.37
3.23
3.89
3.52
2.7
3.21
3.5
4.16
3.78
3.12
Operating Profit
0.22
-0.11
0.41
0.06
0.72
-0.11
0.24
-0.26
0.42
0.79
0.28
-0.45
0.19
OPM %
5.85%
-2.31%
7.39%
1.35%
18.23%
-2.91%
6.38%
-10.66%
11.57%
18.41%
6.31%
-13.51%
5.74%
Other Income
-0.01
0.01
0
0.01
0
0.02
0.01
0
0
0.06
0
0
0
Interest
0.02
0
0
0.05
0
0
0
0
0
0
0
0
0
Depreciation
0
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.03
0.04
0.04
0.04
PBT
0.19
-0.12
0.39
0
0.7
-0.11
0.23
-0.29
0.39
0.82
0.24
-0.49
0.15
Tax %
0%
0%
0%
—
0%
0%
0%
41.38%
0%
0%
0%
51.02%
0%
Net Profit
0.18
-0.12
0.39
-0.18
0.7
-0.11
0.22
-0.41
0.39
0.82
0.24
-0.74
0.16
EPS (₹)
0.4
-0.27
0.87
-0.4
1.56
-0.25
0.49
-0.92
0.87
1.83
0.54
-1.65
0.36
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8.84
10.36
12.23
11.3
11.28
10.59
9.96
14.16
13.15
18.5
13.86
15.59
15.37
Expenses
8.65
10
11.86
10.96
10.98
10.34
9.83
13.84
12.71
17.93
13.34
14.64
14.56
Operating Profit
0.19
0.36
0.37
0.34
0.3
0.25
0.13
0.32
0.44
0.57
0.52
0.95
0.81
OPM %
2.15%
3.47%
3.03%
3.01%
2.66%
2.36%
1.31%
2.26%
3.35%
3.08%
3.75%
6.09%
5.27%
Other Income
0.09
0.08
0.11
0.04
0.1
0.26
0.22
0.19
0.03
0.01
0.11
0.16
0.06
Interest
0.01
0.1
0.1
0.02
0.01
0.12
0.17
0.13
0.06
0.05
0.01
0.01
0
Depreciation
0.09
0.08
0.09
0.1
0.09
0.08
0.08
0.08
0.08
0.08
0.1
0.14
0.15
PBT
0.18
0.26
0.29
0.26
0.3
0.31
0.1
0.3
0.33
0.45
0.52
0.96
0.72
Tax %
0%
0%
0%
0%
0%
0%
0%
16.67%
15.15%
40%
23.08%
26.04%
—
Net Profit
0.17
0.26
0.3
0.26
0.3
0.31
0.1
0.25
0.28
0.28
0.41
0.7
0.48
EPS (₹)
0.38
0.58
0.67
0.58
0.67
0.69
0.22
0.56
0.62
0.62
0.92
1.56
1.08
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
Reserves
-4.09
-3.83
-3.54
-3.27
-2.97
-2.67
-2.56
-2.31
-2.03
-1.75
-1.34
-0.64
Borrowings
0.4
0
0.05
0
0
0
0
0
0
0
0
0
Other Liabilities
2.51
2.28
2.79
2.75
2.15
1.9
1.61
1.28
0.96
2.2
1.42
1.67
Total Liabilities
3.3
2.93
3.78
3.96
3.66
3.71
3.53
3.45
3.41
4.93
4.56
5.51
Fixed Assets
1.09
1.03
1.22
1.16
1.12
1.14
1.12
1.07
1.1
1.12
1.2
1.3
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
2.21
1.9
2.56
2.8
2.54
2.57
2.41
2.38
2.31
3.81
3.36
4.21
Total Assets
3.3
2.93
3.78
3.96
3.66
3.71
3.53
3.45
3.41
4.93
4.56
5.51
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-0.7
0.41
0.39
0.14
-0.12
0.39
-0.7
0.28
-0.26
1.03
-0.04
1.24
Investing
-0.09
-0.02
-0.28
0.06
0.04
-0.1
-0.06
-0.02
-0.1
-0.11
-0.18
-0.23
Financing
0.4
-0.4
0.05
-0.05
0.23
0
0
0
-0.06
-0.05
-0.01
-0.01
Net Cash Flow
-0.38
-0.01
0.15
0.15
0.16
0.29
-0.77
0.25
-0.42
0.86
-0.23
1
Free Cash Flow
-0.78
0.39
0.11
0.2
-0.08
0.29
-0.76
0.26
-0.36
0.92
-0.22
1.01
CFO/OP
-368
114
105
41
-37
204
-408
88
-48
189
19
156
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
28.08
28.54
19.4
25.19
43.36
39.64
35.91
18.04
29.14
31.76
39.77
31.61
Inventory Days
35.62
22.76
40.83
39.4
22.92
21.37
55.6
34.08
38.92
29.56
32.92
19.1
Days Payable
122
94.35
98.2
106
87.5
82.79
77.35
39.81
32.1
47.85
37.39
39.71
Cash Conversion Cycle
-58.78
-43.06
-37.97
-41.63
-21.22
-21.79
14.16
12.31
35.97
13.47
35.29
10.99
Working Capital Days
-46.66
-28.19
-24.17
-21.96
-8.41
-9.31
22.72
17.27
37.19
14.6
34.24
21.31
ROCE %
37.62%
50%
47.56%
25.45%
22.79%
25.9%
14.48%
21.03%
16.88%
19.31%
18.06%
27.79%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Unjha Formulations insights

62 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

Public56.72%Others6.35%Promot.36.92%As ofSep 2026

Documents

Frequently Asked Questions about Unjha Formulations

What does Unjha Formulations Ltd do?
Incorporated in 1991, Unjha Formulations Ltd is a manufacturer and exporter of psyllium husk-based products.[1]
Where is Unjha Formulations Ltd (UNJHAFOR) listed?
Unjha Formulations Ltd trades under code 531762 on the BSE.
Which sector does Unjha Formulations Ltd belong to?
Unjha Formulations Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Unjha Formulations Ltd?
Unjha Formulations Ltd has a market capitalisation of ₹12.12 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Unjha Formulations Ltd?
Unjha Formulations Ltd trades at a PE ratio of 24.99 as of 28 Oct 2026, on earnings per share of ₹1.08, against a book value of ₹8.58 per share.
What is the 52-week high and low of Unjha Formulations Ltd?
Over the last 52 weeks Unjha Formulations Ltd has traded between ₹17.52 and ₹36.38 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Unjha Formulations Ltd?
Unjha Formulations Ltd reported a return on equity of 18.34%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1991, Unjha Formulations Ltd is a manufacturer and exporter of psyllium husk-based products.[1]

Website unjhaformulations.com
Face Value ₹ 10
Shares Outstanding 44,90,209

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531762.md for Unjha Formulations Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month